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INTRODUCTION 
Liver cancer is the sixth most common 
cancer worldwide and the third leading 
cause of death from cancer. Liver cancer is 
more prevalent in countries in East Asia, 
Southeast Asia and the western Central 
Africa.1 Liver cancer rates in North America 
and Western Europe, less than 10 cases per 
hundred thousand people in Asia and Africa 
between 50-150 cases per hundred thousand 
people.2 The incidence of cancer in many 
countries such as the United States and 
Central America and Europe is on the rise 
because it is caused by the epidemic of 
obesity and increasing cases of HCV 
infection due to intravenous drug. In 
contrast, in high-risk areas, decreasing trend 
has been observed Because of widespread 
vaccination against HBV infection in adults 
and children.1 The aim of this study was to 
estimate the level and trend of mortality 
from liver cancer in Iranian population 
during 2006-2010 .The overall view of the 
process as far as mortality due to these 
cancers in Iran is provided. 
In this study, Data related to the number 
of deaths caused by Liver cancer during 
2006 to 2010 in 29 provinces by the 
Network Management Centre, Department 
of Information Management and 
Technology and Applied Research of the 
Ministry of health and Medical Education 
from various sources including government 
organizations, cemeteries, hospitals, homes 
and the Ministry of Health and Medical 
Education were collected.3 
The results of calculation of mortality 
rates per hundred thousand people showed 
that the rate of death from liver cancer was 
4.78 in 2006 to 5.37 in 2010. In Table 1, the 
mortality rate in all the years under the study 
suggests that liver cancer in men is more 
than in women. 
The results show that the mortality of 
liver cancer has been increased; this trend is 
consistent with previous studies.
4
 Deaths 
from cancer in the UK have increased by 2.6 
per hundred thousand people.5 Rates of liver 
cancer mortality in the age groups under the 
study show that it increases with the 
increasing age of the cancer death rate and 
most deaths have been reported in patients 
aged over than 70 years. Based on the 
results of the present study, death from liver 
cancer in men has more increases with age 
than in women. 
Epidemiology and trends in mortality from liver cancer in Iran 
 
Sepideh Mahdavi
1
, Neda Amoori
2
, Hamid Salehiniya
3
, Mostafa Enayatrad
4*
 
1
Epidemiology and Biostatistics Dept., Medical University Shahid Sadoughi, Yazd, I.R. 
Iran; 
2
Epidemiology and Biostatic Dept., Abadan University of Medical Sciences, 
Abadan, I.R. Iran; 
3
Minimally Invasive Surgery Research Center, Iran University of 
Medical Sciences, Tehran, I.R. Iran; 
4
Epidemiology Dept., Shahid Beheshti University of 
Medical Sciences, Tehran, I.R. Iran. 
Received: 13/Sep/2015 Accepted: 14/Oct/2015 
L
etter to
 th
e ed
ito
r
 
Mahdavi S, et al. Mortality from liver cancer in Iran 
240 
How to cite the article: Mahdavi S, Amoori N, Salehiniya H, Enayatrad M. Epidemiology and 
trends in mortality from liver cancer in Iran. Int J Epidemiol Res. 2015; 2(4): 239-240. 
Table 1: Mortality from Liver cancer per hundred thousand people in the study group sex 
Year of Study 
 
Mortality per hundred thousand Crude mortality rate Sex ratio (M/F) 
Woman Man Total Woman Man Total 
2006 3.81 5.72 4.78 1072 1659 2731 1.54 
2007 4.21 5.85 5.04 1103 1573 2677 1.42 
2008 4.41 5.84 5.13 1170 1587 2757 1.35 
2009 4.09 6.06 5.09 1100 1668 2769 1.51 
2010 4.51 6.12 5.37 1258 1706 2964 1.35 
Total  5703 8193 13898 1.43 
 
Because both hepatitis B and hepatitis C 
are the major causes of liver cancer, treatment 
can reduce the risk of cancer, although this 
effect is not clear. It is estimated that 
approximately 1.5 million people in the 
country are infected with hepatitis B of which 
more than 15% to 40% are at risk of 
developing cirrhosis or liver cancer.6 The 
mass vaccination is a safe and easy way to 
control hepatitis B in the population, which 
can reduce infection rates by up to 95%. The 
universal vaccination against hepatitis B in 
Iran from 1993 to 2006 and applying it to 
more than 94% is reached.7 It is expected that 
the effect of reducing the burden of 
developing liver cancer occurs in the next 
decade. Since that time an attention on the 
course of hepatitis B and liver cancer and the 
virus vaccination for infants is recommended. 
It is also recommended that screening be 
performed for people with hepatitis B to 
identify cases of liver cancer. 
 
REFERENCES 
1. Jemal A, Center MM, DeSantis C, Ward 
EM. Global patterns of cancer incidence and 
mortality rates and trends. Cancer 
Epidemiol Biomarkers Prev. 2010; 19(8): 
1893-907. 
2. Fallahzadeh H, Cheraghi M, Amoori N, 
Alaf M. Red meat intake and risk of non-
Hodgkin lymphoma: a meta-analysis. 
Asian Pac J Cancer Prev. 2014; 15(23): 
10421-5. 
3. Khosravi A, Aghamohamadi S, Kazemi 
E, Pour Malek F, Shariati M. Mortality 
profile in Iran (29 provinces) over the 
years 2006 to 2010. Tehran: Ministry of 
Health and Medical Education.; 2013. 
4. Fazeli Z, Abadi AR, Pourhoseingholi 
MA, Taghinejad H. Studying of liver 
cancer mortality and morbidity burden in 
Iran. J Ilam Univ Med Sci.  2012; 20(4). 
117-22. 
5. Ladep NG, Khan SA, Crossey MM, 
Thillainayagam AV, Taylor-Robinson SD, 
Toledano MB. Incidence and mortality of 
primary liver cancer in England and 
Wales: changing patterns and ethnic 
variations. World J Gastroenterol. 2014; 
20(6): 1544-53. 
6. Moayed Alavian SH, Ahmadzad-Asl M, 
Bagheri Lankarani K. Hepatitis B Virus 
infection in Iran. Hepatitis. 2008: 281-94. 
7. Alavian SM, Fallahian F, Lankarani 
KB. The changing epidemiology of viral 
hepatitis B in Iran. J Gastrointestin Liver 
Dis. 2007; 16(4): 403-6. 
 
 
 
